Chimeric Antigen Receptor (CAR)-T cell therapy is a therapeutic approach whereby T-cells are engineered with a synthetic receptor for increased tumor targeting specificity and tumor cytotoxicity.
IMPT-601 is designed to overcome the suppressive tumor microenvironment by enhancing CAR T- cell infiltration, overcoming T-cell exhaustion, and reducing regulatory T-cell activity LOS ANGELES, Oct.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback